[A25-115] Concizumab (haemophilia B) – Addendum to Project A25-56
Last updated 16.10.2025
Project no.:
A25-115
Commission:
Commission awarded on 09.09.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Routine prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency) and factor IX inhibitors and of 12 years of age or more
Unchanged after addendum: Added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A25-115
| Project no. | Title | Status |
|---|---|---|
| A25-56 | Concizumab (haemophilia B) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
16-10-2025 A G-BA decision was published.
G-BA documents on this decision